Position statement: asthma in Latin America. IS short-acting beta-2 agonist helping or compromising asthma management?

References

• Forno E, Gogna M, Cepeda A, Yañez A, Solé D, Cooper P, Avila L, Soto-Quiros M, Castro-Rodriguez JA, Celedón JC, et al. Asthma in Latin America. Thorax. 2015;70(9):898–905. doi:10.1136/thoraxjnl-2015-207199.
   PubMed Web of Science ®Google Scholar
• The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018.
   Google Scholar
• Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol. 2013;41(2):73–85. doi:10.1016/j.aller.2012.03.001.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, Maspero JF, Moreno-Cantu JJ, Fish JE, Murphy K, et al. Taking aim at asthma around the world: global results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734–742.e5. doi:10.1016/j.jaip.2015.04.013.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706.
   PubMed Web of Science ®Google Scholar
• Ebmeier SJ, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality rates. Lancet. 2017;390(10098):935–945. doi:10.1016/S0140-6736(17)31448-4.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, Blais L, McNutt M, Buist AS, Spitzer WO. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–610. doi:10.1164/ajrccm.149.3.8118625.
   PubMed Web of Science ®Google Scholar
• A Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94(8):767–771. doi:10.1053/rmed.2000.0820.
   PubMed Web of Science ®Google Scholar
• Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, Town GI. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161(5):1459–1464. doi:10.1164/ajrccm.161.5.9906052.
   PubMed Web of Science ®Google Scholar
• Nannini LJ. Overreliance link between asthmatic subjects and short-acting β2 agonists. Pulm Pharmacol Ther. 2018;50:80–81. doi:10.1016/j.pupt.2018.03.003.
   PubMed Web of Science ®Google Scholar
• Catálogo de Medicamentos Genéricos Intercambiables, México. Available from: http://www.salud.gob.mx/ [last accessed 3 March 2020].
   Google Scholar
• Frey U, Brodbeck T, Majumdar A, Taylor DR, Town GI, Silverman M, Suki B. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature. 2005;438(7068):667–670. doi:10.1038/nature04176.
   PubMed Web of Science ®Google Scholar
• Beasley R, Pearce N, Crane J, Burgess C. Beta agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol. 1999;104(2):S18–S30. doi:10.1016/S0091-6749(99)70270-8.
   PubMed Web of Science ®Google Scholar
• Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, Devillier P, Didier A, Leroyer C, Marguet C, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. doi:10.1111/j.1398-9995.2007.01394.x.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:10.1056/NEJMoa1715274.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887. doi:10.1056/NEJMoa1715275.
   PubMed Web of Science ®Google Scholar
• Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. doi:10.1056/NEJMoa1901963.
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928. doi:10.1016/S0140-6736(19)31948-8.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2019. Available from: http://ginasthma.org/ [last accessed 28 January 2020].
   Google Scholar
• Anonymous. Using beta2 stimulants in asthma. Drug Ther Bull. 1997;35:1–4.
   PubMedGoogle Scholar
• Nannini LJ. Treat to target approach for asthma. J Asthma. 2019;57:687–690. doi:10.1080/02770903.2019.1591443.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Recommendations for implementing antimicrobial stewardship programs in Latin America and the Caribbean: manual for Public Health Decision-Makers, 2018.
   Google Scholar